TOKYO--(Marketwire - January 19, 2010) - IntraLinks, the leading provider of critical
information exchange solutions, announced today that Daiichi Sankyo has
selected IntraLinks as the company's information sharing solution. Daiichi
Sankyo now joins the world's top 10 pharmaceutical companies that already
leverage IntraLinks' solution.
With more than 100 years of scientific expertise across a wide range of
therapeutic categories, Daiichi Sankyo draws upon a rich legacy of
innovation and a robust pipeline of promising new compounds. Today Daiichi
Sankyo faces many new challenges including developing new innovative
pharmaceuticals and ongoing communication with global regulatory bodies.
Prior to selecting IntraLinks, Daiichi Sankyo considered a number of
information sharing platforms for managing their highly confidential
business information in a multi-lingual environment without imposing
additional demand on the company's IT resources. With IntraLinks, Daiichi
Sankyo now manages, organizes, tracks and shares critical information both
inside and outside the enterprise with 24/7/365 live system support around
"We are extremely pleased to introduce the IntraLinks solution to
facilitate secure and speedy information exchange inside and outside the
company's firewall. We plan to use IntraLinks strategically across diverse
departments in the near future to raise our standard of operational
efficiency," said Mr. Yasuhiro Ikeda, General Manager, IT Strategy
Department of Daiichi Sankyo.
"We are delighted that IntraLinks has been selected by Daiichi Sankyo. As a
Software-as-a-Service solution, IntraLinks requires no additional hardware,
software, or additional demands on IT resources. Hence our customers can
gain tremendous cost efficiencies with a solution that can be implemented
in near real-time. We believe the decision by Daiichi Sankyo is yet
another testament to the effectiveness of our solution, which has already
been widely deployed within the pharmaceutical industry," said Rob Mullen,
EVP of Worldwide Sales for IntraLinks.
IntraLinks provides on-demand solutions for businesses to securely
collaborate, communicate and exchange critical information inside and
outside the enterprise. For more than a decade, 750,000 professionals from
more than 90,000 organizations have relied on IntraLinks to accelerate
workflow, optimize business processes and realize new profit potential.
IntraLinks counts 800 of the Fortune 1000 as clients, including AstraZeneca
Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more
information, visit www.intralinks.com.
About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in
2005 through the merger of two leading Japanese pharmaceutical companies.
This integration created a more robust organization that allows for
continuous development of novel drugs that enrich the quality of life for
patients around the world. A central focus of Daiichi Sankyo's research and
development are thrombotic disorders, malignant neoplasm, diabetes mellitus,
and autoimmune disorders. Equally important to the company are hypertension,
hyperlipidemia or atherosclerosis and bacterial infections. For more
information, visit www.daiichisankyo.com.